BridgeBio Oncology Therapeutics Inc. (BBOT) Live Share Price, Invest From India

BridgeBio Oncology Therapeutics Inc. Stock Performance

as on June 27, 2026 at 2:15 pm IST

Day's Low
Day's High
$7.30
Day's Price Range
$7.97
$7.40
1.35%
Downside
7.70%
Upside
52 Week's Low
52 Week's High
$7.00
52-Week Price Range
$14.87
$7.40
5.41%
Downside
100.95%
Upside

BridgeBio Oncology Therapeutics Inc. share price movements today

Previous Close: $7.69
Open: $7.72
Volume: 816.7K
Day's Low - High: $7.30 - $7.97
52 Week Low - High: $7.00 - $14.87

BridgeBio Oncology Therapeutics Inc. Historical Returns

1 Month Return: -8.12 %
3 Month Return: -16.68 %
1 Year Return: 0 %
3 Year Return: 0 %
5 Year Return: 0 %

BridgeBio Oncology Therapeutics Inc. Stock Fundamentals & Key Indicators

Check BridgeBio Oncology Therapeutics Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$601.6M

EPS (TTM)

-2.2322

Dividend Yield

0.00%

PE Ratio (TTM)

PEG Ratio

Return On Equity TTM

-62.21%

BridgeBio Oncology Therapeutics Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of BridgeBio Oncology Therapeutics Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
BridgeBio Oncology Therapeutics Inc.	NA	$601.6M	NA	NA	0.00%	NA
Alnylam Pharmaceuticals Inc.	BUY	$39.3B	67.15%	74.07	12.55%	NA
Vertex Pharmaceuticals Inc.	BUY	$120.6B	147.08%	28.17	35.51%	NA
Regeneron Pharmaceuticals Inc.	BUY	$65.4B	12.64%	15.22	29.65%	0.58%

Indian Investors' Interest in BridgeBio Oncology Therapeutics Inc. Stock

Search interest for BridgeBio Oncology Therapeutics Inc. Stock has decreased by -27% in the last 30 days, reflecting a downward trend in search activity.

Time period: May 29, 2026 to June 28, 2026

Change:-27% versus previous 30 day period

BridgeBio Oncology Therapeutics Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Revenue	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	0	-	-	-	-	0	0
Operating Income	-15	-23	-19	-21	-23	-30	-49	-43	-46
EBITDA	-15	-23	-19	-21	-23	-29	-49	-43	-45
Interest Expense	-	-	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0
Income Before Tax	-15	-21	-17	-19	-22	-28	-44	-38	-42
Income Tax Expense	-	-	-	-	-	-	-	-	-
Net Income	-15	-21	-17	-19	-22	-28	-44	-38	-42
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

BridgeBio Oncology Therapeutics Inc. Annual Profit & Loss

All numbers in Millions USD

	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	-	-
Gross Profit	-	-	0
Operating Income	-64	-80	-145
EBITDA	-64	-80	-145
Interest Expense	-	-	-
Depreciation	0	0	0
Income Before Tax	-64	-74	-134
Income Tax Expense	-	-	-
Net Income	-64	-74	-134
Net Profit Margin	0.00%	0.00%	0.00%

BridgeBio Oncology Therapeutics Inc. Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Net Income	-15	2	-17	1	0	-28	-44	-38	-42
Operating Cash Flow	-8	0	-39	0	0	-23	-70	-42	-35
Investing Cash Flow	2	-	37	-	-	9	65	7	-285
Financing Cash Flow	6	199	19	0	0	18	383	0	0
Change in Cash	0	0	0	0	0	5	408	-35	-321

BridgeBio Oncology Therapeutics Inc. Annual Cash Flow

All numbers in Millions USD

	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	0	0	7	-134
Operating Cash Flow	-	-52	0	-113
Investing Cash Flow	-	-	-184	73
Financing Cash Flow	-	55	186	383
Change in Cash	-	0	1	342

Global Institutional Holdings in BridgeBio Oncology Therapeutics Inc.

Funds	Holdings
Novo A/S	2.73%
LAURION CAPITAL MANAGEMENT LP	2.4%
Adage Capital Partners Gp LLC	0.5%
Aisling Capital Management LP	1.27%
Vanguard Group Inc	0.99%

See all

Insights on BridgeBio Oncology Therapeutics Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

NEGATIVE IMPACT
Price Dip
In the last 3 months, BBOT stock has moved down by -16.7%

About BridgeBio Oncology Therapeutics Inc.

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.

Organisation	BridgeBio Oncology Therapeutics Inc.
Headquarters	256 East Grand Avenue, South San Francisco, CA, United States, 94080
Industry	Biotechnology
CEO	Dr. Pedro J. Beltran M.D., Ph.D.
E-voting on shares	Click here to vote

Key Management of BridgeBio Oncology Therapeutics Inc.

Name	Title
Dr. Neil Kumar Ph.D.	Executive Chairman
Dr. Yong Ben M.B.A., M.D.	Chief Medical & Development Officer
Mr. Marc Cobo	VP of Finance & Controller
Mr. Daniel Watson Ph.D.	Senior Vice President of Chemistry, Manufacturing & Controls
Mr. Rui Xu Ph.D.	Senior Vice President of Drug Discovery
Dr. Frank P. McCormick Ph.D.	Co-Founder, Non-Executive Director & Chair of the Advisory Board
Dr. Pedro J. Beltran M.D., Ph.D.	Chief Executive Officer and Director
Mr. Idan Elmelech M.A., M.B.A.	Chief Operating Officer
Mr. Aaron Chan J.D.	Vice President of Legal
Mr. Bin Wang Ph.D.	Senior Vice President of Drug Discovery

FAQs

What is BridgeBio Oncology Therapeutics Inc. share price today?

BridgeBio Oncology Therapeutics Inc. share price today is $7.4 as on June 27, 2026 at 8:45 am IST at the close of the market. BridgeBio Oncology Therapeutics Inc. share today touched a day high of $7.97 and a low of $7.3.

What is the 52 week high and 52 week low for BridgeBio Oncology Therapeutics Inc. share?

BridgeBio Oncology Therapeutics Inc. share touched a 52 week high of $14.87 on December 8, 2025 and a 52 week low of $7 on June 11, 2026. BridgeBio Oncology Therapeutics Inc. stock price today i.e. June 27, 2026 at 8:45 am IST is closed at $7.4,which is 50.24% down from its 52 week high and 5.71% up from its 52 week low.

What is BridgeBio Oncology Therapeutics Inc.'s market capitalisation today?

BridgeBio Oncology Therapeutics Inc. market capitalisation is $0.00T as on June 27, 2026 at 8:45 am IST.

How to invest in BridgeBio Oncology Therapeutics Inc. Stock (BBOT) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for BridgeBio Oncology Therapeutics Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in BridgeBio Oncology Therapeutics Inc. Shares that will get you 0.2027 shares as per BridgeBio Oncology Therapeutics Inc. share price of $7.4 per share as on June 27, 2026 at 8:45 am IST.

What is the minimum amount required to buy BridgeBio Oncology Therapeutics Inc. Stock (BBOT) from India?

Indian investors can start investing in BridgeBio Oncology Therapeutics Inc. (BBOT) shares with as little as ₹94.3 or $1 (as of June 28, 2026 at 1:39 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹943.00 in BridgeBio Oncology Therapeutics Inc. stock (as per the Rupee-Dollar exchange rate as on June 28, 2026 at 1:39 am IST). Based on BridgeBio Oncology Therapeutics Inc. share’s latest price of $7.4 as on June 27, 2026 at 8:45 am IST, you will get 1.3514 shares of BridgeBio Oncology Therapeutics Inc.. Learn more about fractional shares .